- Study: OTC ibuprofen as effective as Rx in treating post-operative pain after having tonsils removed
- FDA advisory panel to consider OTC status of NSAIDs
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
IRVINE, Calif. Ista Pharmaceuticals has won approval from the Food and Drug Administration for a drug used to treat eye surgery patients.
The drug maker announced the approval of Bromday (bromfenac) ophthalmic solution as a once-daily eye drop for treating pain and inflammation in patients who have received cataract extraction surgery. The drug is a nonsteroidal anti-inflammatory drug, or NSAID, belonging to the same class as the common painkiller ibuprofen. The company plans to launch the drug at the end of this year.
“We believe the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery,” Ista president and CEO Vicente Anido said. “Bromday is an important addition to our growing prescription eye and allergy product portfolio.